December 2015, Vol. 4, No. 6

← Back to Issue

Sample Size Calculation for Single-Arm Phase 2 Prostate Cancer Trials

Prostate Cancer

Prostate cancer remains one of the major health issues for men worldwide and is the second leading cause of cancer-related death in males in the United States…

Download FullArticle

 
Interview with the Innovators - December 28, 2015

The Current Landscape in Melanoma Treatment

An Interview with Jeffrey Infante, MD, of Sarah Cannon Research InstituteThe COMBI-d and COMBI-v trials showed that treating BRAF V600 mutation–positive metastatic melanoma with the combination of da­brafenib plus trametinib resulted in a significant increase in overall survival and a 33% reduction in the risk of progression or death compared [ Read More ]

European Cancer Congress - December 28, 2015

Oncotype DX Breast Cancer Assay Spares Low-Risk Patients from Chemotherapy

Patients with early breast cancer and a low Oncotype DX Recurrence Score (RS) can be safely treated with hormone therapy alone and avoid chemotherapy, according to results from the National Cancer Institute–sponsored TAILORx trial.1,2 Patients who had an RS of <11 treated with hormone therapy alone had less than a [ Read More ]